Introduction: Serological nuclear and antimicrobial antibodies are predictive markers of disease course and complications in ulcerative colitis (UC) and Crohn's disease (CD). The stability of serological titers over time has been questioned.
Aim:
We wanted to compare antibody titers before and after treatment in newly diagnosed treatment naive pediatric patients with inflammatory bowel disease (IBD). Methods: Patients <18 years, altogether 57 patients, 38 with CD and 19 with UC were diagnosed with IBD between 2005 and 2007. Blood specimens were analyzed for antibodies (Prometheus labs, San Diego) at diagnosis and again after 1 2 years of treatment. Results: Thirteen (68%) of the UC patients and 13 (34%) of the CD patients were ANCA-positive (p = 0.02). In CD and UC patients respectively, the median titers in EU/ml against I2, Anti-Omp C, ASCA IgA, ASCA IgG and CBir, were not statistically significantly different after treatment compared to baseline. The titers against ASCA IgA and IgG were significantly higher at diagnosis in CD patients (8.4 and 11.9) compared to UC patients (3.1 and 3.1), p = 0.01 and <0.01. The same differences between patients with CD (7.5 and 12.8) and UC (3.1 and 6) were found after treatment, p = <0.01 and 0.03, regardless whether the patients had received infliximab treatment (18/38 CD patients) or not. Conclusion: The study demonstrates reproducibility of the presence and titers of serological antibodies from the time of diagnosis until 1 2 years of follow-up. Serological markers may be applied as prognostic markers in IBD even after years of treatment.
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Idiopathic thrombocytopenic purpura associated to pediatric Crohn's disease; diagnostic and therapeutic implications Introduction: Inflammatory bowel disease (IBD) is often associated to extra-intestinal manifestations. Among these, hematologic autoimmune thrombocytopenia or idiopathic thrombocytopenic purpura (ITP) has been rarely reported. Study Cases: Case 1: A 9-year-old girl with Crohn's disease (CD) on maintenance treatment with azathioprine (AZA), presented with ecchymosis, petechiae, and isolated thrombocytopenia (2000/mm 3 ). ITP was diagnosed and treatment with intravenous gammaglobulin (0.8 mg/kg/dose) and steroids (2 mg/kg/day) is started, with good response and posterio management with periodic gammaglobulin. Six months later, after stopping AZA, she experienced a relapse of her CD, associated to peripheral arthritis. Treatment with Adalimumab (ADA) was started, with good control of her digestive and joint symptoms and with no further need of treatment for her ITP. Case 2: A 15-year-old male with spastic diplegia secondary to perinatal anoxia, and ileocolonic CD, received exclusive enteral nutrition and AZA after diagnosis, achieving remission. Due to digestive intolerance, AZA was switched to mercaptourine, with good response. Seven months after diagnosis, isolated thrombocytopenia (85000/mm 3 ) was detected, leading to the diagnosis of ITP. He received gammaglobulin with good response, but subsequently needed maintenance treatment with steroids (0.5 mg/kg/day). Due to severe acne and low bone mineral density, treatment with ADA is being currently evaluated. Conclusions: The association of IBD and ITP has been poorly communicated. Differential diagnosis with drug toxicity and other concurrent processes should be done. The good response of both entities to anti-TNF treatment suggests shared pathogenetic mechanisms. This treatment may be an alternative conventional therapies. 
